www.biomedcentral.com

Table 2
MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up
Pat.	Dose (mg)^#	MRI-FU	Lesion (no.)	Size (mm)	T1	T2 fs	Necr.	[NT]/[TV] (%)	Sum (mm)

1	-	baseline	liver	25	2	4	-	-	25
	800	3 w.	(1)	30	4	4	↑	<25	30
	800	8 w.		30	2	5	↑	<25	30
	800	16 w.		34	2	5	↑	<25	34

2	-	baseline	liver	160	2	3	+	<50	170
	400	2 w.	(2)	165	4	5	↑	<50	175
	800	6 w.		160	4	3	↑	<75	172
	400	14 w.		155	2	3	↑	>75	172

3	-	baseline	liver	35	2	4	-	-	35
	800	2 w.	(4)	35	2	4	-	-	35
	200	6 w.		35	2	4	-	-	35
	200	12 w.		39	4	3	↑	<25	39

4	-	baseline	liver	57	3	4	+	<25	57
	800	4 w.	(1)	57	4	5	↔	<25	57

5	-	baseline	liver	30	2	4	+	<25	30
	800	2 w.	(1)	30	2	4	↔	<25	30
	800	6 w.		31	2	5	↔	<25	31
	400	13 w.		30	2	5	↔	<25	30
	400	20 w.		40	2	5	↔	<25	40

6	-	baseline	liver	133	2	4	+	<25	133
	800	3 w.	(1)	135	3	5	↑	<25	135
	800	7 w.		130	2	3	↔	<25	130

7	-	baseline	liver	38	2	2	+	<25	70
	800	2 w.	(3)	45	5	4	↑	>75	80
	-	8 w.		32	3	3	↓	<50	66
	400	16 w.		32	3	3	↓	<25	71

8	-	baseline	adrenal	45	3	3	+	<25	144
	800	3 w.	(3)	45	5	4	↑	<25	144
	400	8 w.		57	5	4	↑	<25	156

9	-	baseline	liver	20	2	4	-	-	119
	800	5 w.	(3)	22	4	5	↑	>75	123
	800	14 w.		20	4	5	↑	>75	119
	800	20 w.		20	2	4	↑	>75	119

10	-	baseline	perit.	12	2	3	-	-	12
	800	2 w.	(2)	12	3	5	↑	+*	12
	800	7 w.		6	3	3	↔	+*	6
	400	15 w.		0	-	-	-	-	0
	400	23 w.		0	-	-	-	-	0

11	-	baseline	liver	10	2	4	-	-	19
	800	3 w.	(2)	14	2	4	-	-	26
	800	7 w.		17	2	4	-	-	31
	800	15 w.		18	2	4	-	-	35
	800	22 w.		21	2	4	-	-	38

12	-	baseline	adrenal	15	2	4	+	<25	50
	800	4 w.	(2)	12	2	4	↑	<50	42
	800	12 w.		8	2	5	↑	<50	36
	200	19 w.		8	2	5	↔	<50	38

13	-	baseline	liver	38	3	4	+	<25	38
	400	3 w.	(1)	38	3	3	↑	<25	38
	-	7 w.		55	4	3	↑	<25	55
	200	15 w.		39	3	3	↑	<50	39

14	-	baseline	liver	17	5	2	+	<25	70
	800	2 w.	(2)	17	5	2	↔	<25	70
	800	5 w.		17	5	2	↑	<50	70
	200	15 w.		17	5	2	↔	<50	70
	400	23 w.		17	5	2	↑	>75	70

15	-	baseline	bone	45	4	2	-	-	149
	800	5 w.	(3)	55	5	4	↑	>75	176
	800	9 w.		45	4	5	↔	>75	193
	800	16 w.		44	4	4	↔	>75	172
	800	21 w.		45	5	4	↔	>75	168
	800	24 w.		50	5	3	↔	>75	163
	800	32 w.		60	4	3	↔	>75	172

16	-	baseline	liver	52	4	2	+	<25	83
	400	3 w.	(2)	52	4	2	↔	<25	83
	-	9 w.		52	3	2	↔	<25	83

17	-	baseline	liver	51	1	4	+	<25	93
	800	4 w.	(2)	57	4	5	↑	>75	107

18	-	baseline	liver	120	1	4	+	<50	120
	800	7 w.	(1)	130	1	4	↓	<50	130

19	-	baseline	liver	151	1	4	+	<25	201
	400	6 w.	(2)	155	4	2	↑	<50	210
	800	18 w.		165	5	5	↑	>75	229

20	-	baseline	liver	15	3	3	-	-	15
	400	2 w.	(1)	15	5	4	↑	<50	15

21	-	baseline	liver	62	2	4	-	-	88
	400	8 w.	(2)	75	4	5	↑	<50	97
	200	15 w.		75	4	5	↔	<50	97
	200	22 w.		81	3	3	↔	<50	96
	200	29 w.		98	5	5	↓	<50	113

Abbreviations: Pat.: patient number. #Daily dose at the time point of each MRI imaging study. MRI-FU: MRI at follow-up; w.: week after therapy initiation. Lesion: location of representative analysed lesion and number of total lesions at this location. Size: size of the representative tumor lesion im mm. T1: T1-weighted image. T2fs: T2-weighted fat saturated image. Qualitative assessment of signal in relation to the signal of liver parenchyma (1 = markedly hypointense; 2 = slightly hypointense; 3 = isointense; 4 = slightly hyperintense; 5 = markedly hyperintense). PV: portal vein; perit.: peritoneal. Gd: Gadolinium-enhancement at baseline and its evolution at follow-up (↑ = increase; ↓ = decrease; ↔ = unchanged; (-) no necrosis detectable; (+) necrosis at baseline detectable). [NT]/[TV]% = percentage of necrosis volume to total tumor volume, expressed as a score with (--) no necrosis, <25%, <50%, <75%, or >75%. Sum (mm) = sum of the diameter of all detectable lesions at this location. +* = the necrotic areas could not be reliably quantified.
Horger et al. BMC Cancer 2009 9:208 doi:10.1186/1471-2407-9-208

Table 2